Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 5378961, 12 pages
https://doi.org/10.1155/2018/5378961
Research Article

The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota

School of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, China

Correspondence should be addressed to Qinhe Yang; nc.ude.unj@hqgnayt

Received 13 November 2017; Accepted 23 January 2018; Published 21 February 2018

Academic Editor: Kamal D. Moudgil

Copyright © 2018 Shu Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Benedict and X. Zhang, “Non-alcoholic fatty liver disease: An expanded review,” World Journal of Hepatology, vol. 9, no. 16, pp. 715–732, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer, “Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes,” Hepatology, 2015. View at Publisher · View at Google Scholar
  3. I. Mikolasevic, S. Milic, T. T. Wensveen et al., “Nonalcoholic fatty liver disease - A multisystem disease?” World Journal of Gastroenterology, vol. 22, no. 43, pp. 9488–9505, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. C.-Y. Chao, R. Battat, A. Al Khoury, S. Restellini, G. Sebastiani, and T. Bessissow, “Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article,” World Journal of Gastroenterology, vol. 22, no. 34, pp. 7727–7734, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two “Hits”?” Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Tilg and A. R. Moschen, “Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,” Hepatology, vol. 52, no. 5, pp. 1836–1846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. V. K. Ridaura, J. J. Faith, and F. E. Rey, “Gut microbiota from twins discordant for obesity modulate metabolism in mice,” Science, vol. 341, no. 6150, Article ID 1241214, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Boursier, O. Mueller, M. Barret et al., “The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota,” Hepatology, vol. 63, no. 3, pp. 764–775, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Doulberis, G. Kotronis, D. Gialamprinou, J. Kountouras, and P. Katsinelos, “Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota,” Metabolism - Clinical and Experimental, vol. 71, pp. 182–197, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Poeta, L. Pierri, and P. Vajro, “Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease,” Children, vol. 4, no. 8, p. 66, 2017. View at Publisher · View at Google Scholar
  11. A. Wree, M. D. McGeough, C. A. Peña et al., “NLRP3 inflammasome activation is required for fibrosis development in NAFLD,” Journal of Molecular Medicine, vol. 92, no. 10, pp. 1069–1082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-G. Wang, W.-L. Fang, J. Wei et al., “The involvement of NLRX1 and NLRP3 in the development of nonalcoholic steatohepatitis in mice,” Journal of the Chinese Medical Association, vol. 76, no. 12, pp. 686–692, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-J. Kim and E.-K. Jo, “NLRP3 inflammasome and host protection against bacterial infection,” Journal of Korean Medical Science, vol. 28, no. 10, pp. 1415–1423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Vandanmagsar, Y.-H. Youm, A. Ravussin et al., “The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance,” Nature Medicine, vol. 17, no. 2, pp. 179–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Q. Shi, Y. C. Fan, and W. Y. Liu, “Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis,” Molecular Biology Reports, vol. 39, no. 10, pp. 9715–9722, 2012. View at Publisher · View at Google Scholar
  16. H. Yao, Y.-J. Qiao, Y.-L. Zhao et al., “Herbal medicines and nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 22, no. 30, pp. 6890–6905, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-J. Zhang, Z.-X. Chen, K.-P. Jiang, Y.-H. Cheng, and Y.-L. Gu, “The effect of QuYuHuaTanTongLuo Decoction on the non-alcoholic steatohepatitis,” Complementary Therapies in Medicine, vol. 16, no. 4, pp. 192–198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Liu, J. Zhao, Y. Li et al., “Artemisia capillaris formula inhibits hepatic steatosis via an MIR-122-induced decrease in fatty acid synthase expression in vivo and in vitro,” Molecular Medicine Reports, vol. 13, no. 6, pp. 4751–4758, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. X.-W. Gong, Y.-J. Xu, Q.-H. Yang et al., “Effects of Soothing Liver and Invigorating Spleen Recipes on the IKK β -NF- κb Signaling Pathway in Kupffer Cells of Nonalcoholic Steatohepatitis Rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 687690, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. Q. H. Yang, Y. J. Xu, Y. Z. Liu, and etal., “Effects of chaihu-shugan-san and shen-ling-bai-zhu-san on p38 mapk pathway in kupffer cells of nonalcoholic steatohepatitis,” Evidence-based Complementary & Alternative Medicine (eCAM), vol. 2014, no. 3, Article ID 671013, 2014. View at Publisher · View at Google Scholar
  21. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases,” Hepatology. View at Publisher · View at Google Scholar
  22. S. Bashiardes, H. Shapiro, S. Rozin, O. Shibolet, and E. Elinav, “Non-alcoholic fatty liver and the gut microbiota,” Molecular Metabolism, vol. 5, no. 9, pp. 782–794, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Schneeberger, A. Everard, A. G. Gómez-Valadés et al., “Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice,” Scientific Reports, vol. 5, Article ID 16643, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Zhao, W. Liu, J. Wang et al., “Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice,” Molecular Endocrinology, vol. 58, no. 1, pp. 1–14, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Qin, Y. Li, Z. Cai, and etal., “A metagenome-wide association study of gut microbiota in type 2 diabetes,” Nature, vol. 490, no. 7418, pp. 55–60, 2012. View at Publisher · View at Google Scholar
  26. M. Remely, B. Hippe, J. Zanner, E. Aumueller, H. Brath, and A. G. Haslberger, “Gut microbiota of obese, type 2 diabetic individuals is enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after weight loss,” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 16, no. 2, pp. 99–106, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. J.-P. Liu, W.-L. Zou, S.-J. Chen et al., “Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development,” World Journal of Gastroenterology, vol. 22, no. 32, pp. 7353–7364, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Özkul, M. Yalinay, T. Karakan, and G. Yilmaz, “Determination of certain bacterial groups in gut microbiota and endotoxin levels in patients with nonalcoholic steatohepatitis,” The Turkish Journal of Gastroenterology, vol. 28, no. 5, pp. 361–369, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. D. P. Singh, P. Khare, V. Bijalwan et al., “Coadministration of isomalto-oligosaccharides augments metabolic health benefits of cinnamaldehyde in high fat diet fed mice,” BioFactors, vol. 43, no. 6, pp. 821–835, 2017. View at Publisher · View at Google Scholar
  30. L. Zhu, S. S. Baker, C. Gill et al., “Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH,” Hepatology, vol. 57, no. 2, pp. 601–609, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Bode and J. C. Bode, “Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol?” Alcoholism: Clinical and Experimental Research, vol. 29, no. 11, supplement, pp. 166s–171s, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Volynets, M. A. KüPer, S. Strahl et al., “Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD),” Digestive Diseases & Sciences, vol. 57, no. 7, pp. 1932–1941, 2012. View at Google Scholar
  33. B. Stecher, “The roles of inflammation, nutrient availability and the commensal microbiota in enteric pathogen infection,” Microbiology Spectrum, vol. 3, no. 3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. M. A. Borton, A. Sabag-Daigle, J. Wu et al., “Chemical and pathogen-induced inflammation disrupt the murine intestinal microbiome,” Microbiome, vol. 5, no. 1, article no. 47, 2017. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Jia, M. Hanate, W. Aw et al., “Eggshell membrane powder ameliorates intestinal inflammation by facilitating the restitution of epithelial injury and alleviating microbial dysbiosis,” Scientific Reports, vol. 7, Article ID 43993, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. M. de la Fuente, L. Franchi, and D. Araya, “Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome,” International Journal of Medical Microbiology, vol. 304, no. 3-4, pp. 384–392, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Seo, N. Kamada, R. Muñoz-Planillo et al., “Distinct commensals induce interleukin-1β via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury,” Immunity, vol. 42, no. 4, pp. 744–755, 2015. View at Publisher · View at Google Scholar
  38. R. J. Chiodini, S. E. Dowd, S. Galandiuk, B. Davis, and A. Glassing, “The predominant site of bacterial translocation across the intestinal mucosal barrier occurs at the advancing disease margin in Crohn's disease,” Microbiology, 2016. View at Publisher · View at Google Scholar
  39. S. Vrakas, K. C. Mountzouris, G. Michalopoulos et al., “Intestinal bacteria composition and translocation of bacteria in inflammatory bowel disease,” PLoS ONE, vol. 12, no. 1, Article ID e0170034, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Ciftci, M. Ozdemir, M. Aktan, and K. Aslan, “Bacterial translocation and intestinal injury in experimental necrotizing enterocolitis model,” Bratislava Medical Journal, vol. 113, no. 4, pp. 206–210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Sheng, P. K. Jena, H.-X. Liu et al., “Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation,” Scientific Reports, vol. 7, no. 1, article no. 1748, 2017. View at Publisher · View at Google Scholar · View at Scopus
  42. T. J. Kim, D. H. Sinn, Y. W. Min et al., “A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease,” Journal of Gastroenterology, pp. 1–10, 2017. View at Publisher · View at Google Scholar · View at Scopus
  43. C. He, Z. Yang, D. Cheng et al., “Helicobacter pylori Infection Aggravates Diet-induced Insulin Resistance in Association With Gut Microbiota of Mice,” EBioMedicine, vol. 12, pp. 247–254, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Zhang, H. Zhang, L. Yu, and Y. Cao, “Helicobacter pylori Dwelling on the Apical Surface of Gastrointestinal Epithelium Damages the Mucosal Barrier Through Direct Contact,” Helicobacter, vol. 19, no. 5, pp. 330–342, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. A. L. Harte, N. F. Da Silva, S. J. Creely et al., “Elevated endotoxin levels in non-alcoholic fatty liver disease,” Journal of Inflammation, vol. 7, article 15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. J. J. Chen, R. Wang, X.-F. Li, and R.-L. Wang, “Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal reg I gene expression,” Experimental Biology and Medicine, vol. 236, no. 7, pp. 823–831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. N. E. Boutagy, R. P. McMillan, M. I. Frisard, and M. W. Hulver, “Metabolic endotoxemia with obesity: Is it real and is it relevant?” Biochimie, vol. 124, pp. 11–20, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. P. D. Cani, J. Amar, M. A. Iglesias et al., “Metabolic endotoxemia initiates obesity and insulin resistance,” Diabetes, vol. 56, no. 7, 1761. View at Google Scholar
  49. S. Fukunishi, T. Sujishi, A. Takeshita et al., “Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats,” Journal of Clinical Biochemistry and Nutrition, vol. 54, no. 1, pp. 39–44, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. J. W. Mao, H. Y. Tang, T. Zhao et al., “Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease,” International Journal of Clinical & Experimental Pathology, vol. 8, no. 4, pp. 3648–3658, 2015. View at Google Scholar
  51. Y. Qiao, P. Wang, J. Qi, L. Zhang, and C. Gao, “TLR-induced NF-κB activation regulates NLRP3 expression in murine macrophages,” FEBS Letters, vol. 586, no. 7, pp. 1022–1026, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Jo, J. K. Kim, D. Shin, and C. Sasakawa, “Molecular mechanisms regulating NLRP3 inflammasome activation,” Cellular & Molecular Immunology, vol. 13, no. 2, pp. 148–159, 2015. View at Publisher · View at Google Scholar
  53. T. Próchnicki, M. S. Mangan, and E. Latz, “Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation,” F1000Research, vol. 5, p. 1469, 2016. View at Publisher · View at Google Scholar
  54. Y.-H. Sui, W.-J. Luo, Q.-Y. Xu, and J. Hua, “Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation,” World Journal of Gastroenterology, vol. 22, no. 8, pp. 2533–2544, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Stienstra, J. A. van Diepen, C. J. Tack et al., “Inflammasome is a central player in the induction of obesity and insulin resistance,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 108, no. 37, pp. 15324–15329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. L. J. Dixon, C. A. Flask, B. G. Papouchado, A. E. Feldstein, and L. E. Nagy, “Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis,” PLoS ONE, vol. 8, no. 2, Article ID e56100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Wen, D. Gris, Y. Lei et al., “Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling,” Nature Immunology, vol. 12, no. 5, pp. 408–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Miura, Y. Kodama, S. Inokuchi et al., “Tolllike receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice,” Gastroenterology, vol. 139, no. 1, pp. 323–334, 2010. View at Publisher · View at Google Scholar · View at Scopus